[go: up one dir, main page]

NO20010322D0 - Heterocykliske forbindelser som inhibitorer av rotamaseenzymer - Google Patents

Heterocykliske forbindelser som inhibitorer av rotamaseenzymer

Info

Publication number
NO20010322D0
NO20010322D0 NO20010322A NO20010322A NO20010322D0 NO 20010322 D0 NO20010322 D0 NO 20010322D0 NO 20010322 A NO20010322 A NO 20010322A NO 20010322 A NO20010322 A NO 20010322A NO 20010322 D0 NO20010322 D0 NO 20010322D0
Authority
NO
Norway
Prior art keywords
inhibitors
heterocyclic compounds
rotamase enzymes
rotamase
enzymes
Prior art date
Application number
NO20010322A
Other languages
English (en)
Other versions
NO20010322L (no
Inventor
Mark Ian Kemp
Michael John Palmer
Mark Allen Sanner
Martin James Wythes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20010322D0 publication Critical patent/NO20010322D0/no
Publication of NO20010322L publication Critical patent/NO20010322L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20010322A 1998-07-21 2001-01-19 Heterocykliske forbindelser som inhibitorer av rotamaseenzymer NO20010322L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9815880.1A GB9815880D0 (en) 1998-07-21 1998-07-21 Heterocycles
PCT/IB1999/001211 WO2000005232A1 (en) 1998-07-21 1999-06-28 Heterocyclic compounds as inhibitors of rotamase enzymes

Publications (2)

Publication Number Publication Date
NO20010322D0 true NO20010322D0 (no) 2001-01-19
NO20010322L NO20010322L (no) 2001-03-15

Family

ID=10835920

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010322A NO20010322L (no) 1998-07-21 2001-01-19 Heterocykliske forbindelser som inhibitorer av rotamaseenzymer

Country Status (45)

Country Link
US (2) US6372736B1 (no)
EP (1) EP1100797B1 (no)
JP (2) JP3795329B2 (no)
KR (2) KR100450008B1 (no)
CN (3) CN1611499A (no)
AP (1) AP2001002046A0 (no)
AR (1) AR019427A1 (no)
AT (1) ATE233261T1 (no)
AU (1) AU765925B2 (no)
BG (1) BG105254A (no)
BR (1) BR9912330A (no)
CA (1) CA2338214C (no)
CO (1) CO5080782A1 (no)
CR (1) CR6073A (no)
DE (1) DE69905582T2 (no)
DK (1) DK1100797T3 (no)
DZ (1) DZ2851A1 (no)
EA (1) EA003513B1 (no)
EE (1) EE200100044A (no)
ES (1) ES2191484T3 (no)
GB (1) GB9815880D0 (no)
GE (1) GEP20033028B (no)
GT (1) GT199900115A (no)
HK (1) HK1039779A1 (no)
HN (1) HN1999000106A (no)
HR (1) HRP20010052A2 (no)
HU (1) HUP0103413A3 (no)
ID (1) ID26991A (no)
IL (1) IL140244A0 (no)
IS (1) IS5790A (no)
MA (1) MA24936A1 (no)
MY (1) MY118222A (no)
NO (1) NO20010322L (no)
NZ (2) NZ522270A (no)
OA (1) OA11585A (no)
PA (1) PA8478501A1 (no)
PE (1) PE20001037A1 (no)
PL (1) PL345734A1 (no)
SI (1) SI1100797T1 (no)
SK (1) SK772001A3 (no)
SV (1) SV1999000102A (no)
TN (1) TNSN99147A1 (no)
TR (1) TR200100135T2 (no)
TW (1) TWI229672B (no)
WO (1) WO2000005232A1 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
JP2002528531A (ja) 1998-11-03 2002-09-03 ビーエーエスエフ アクチェンゲゼルシャフト 置換2−フェニルベンズイミダゾール、その製造法および使用
CO5261615A1 (es) 1999-12-01 2003-03-31 Agouron Pharma Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
DE10124953A1 (de) * 2001-05-21 2002-12-12 Marlies Knipper Substanz für die therapeutische Behandlung von Tinnitus
ES2383123T3 (es) * 2004-06-29 2012-06-18 Aventis Pharmaceuticals Inc. Composición de unión a FKBP y su uso farmacéutico
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US7728026B2 (en) * 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
CN101316834A (zh) * 2005-09-29 2008-12-03 艾博特公司 在2位取代有苯基的1h-苯并咪唑-4-甲酰胺是强效parp抑制剂
ES2342007T3 (es) * 2005-11-15 2010-06-30 Abbott Laboratories 1h-benzimidazol-4-carboxamidas sustituidos eficaces como inhibidores de (parp).
LT1976828T (lt) 2005-12-29 2017-04-25 Celtaxsys, Inc. Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai
GB0602768D0 (en) * 2006-02-10 2006-03-22 Vastox Plc Treatment of muscular dystrophy
SI1986633T1 (sl) 2006-02-10 2015-03-31 Summit Corporation Plc Zdravljenje Duchennove mišične distrofije
RU2462458C2 (ru) * 2006-02-10 2012-09-27 Байомарин Ига Лимитед Лечение миодистрофии дюшена
JP5228237B2 (ja) * 2006-05-02 2013-07-03 アボット・ラボラトリーズ 置換1h−ベンゾイミダゾール−4−カルボキサミドは強力なparp阻害薬である
ES2387471T3 (es) 2006-12-20 2012-09-24 Amgen Inc. Compuestos heterocíclicos y su uso en el tratamiento de la inflamación, la angiogénesis y el cáncer
AR065628A1 (es) * 2007-03-07 2009-06-17 Xenon Pharmaceuticals Inc Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
SI2170396T1 (sl) * 2007-08-03 2017-04-26 Summit (Oxford) Limited Kombinacije zdravil za zdravljenje duchennove mišične distrofije
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
GB0715939D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
WO2010083199A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
GB0905664D0 (en) * 2009-04-02 2009-05-13 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
JP6527851B2 (ja) 2013-03-12 2019-06-05 セルタクシス,インコーポレイテッド ロイコトリエンa4加水分解酵素を阻害する方法
AU2014239585B2 (en) 2013-03-14 2019-04-04 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
BR112015022226A2 (pt) 2013-03-14 2017-07-18 Celtaxsys Inc inibidores de leucotrieno a4 hidrolase
MX2015011678A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
WO2015179414A1 (en) * 2014-05-19 2015-11-26 Merial, Inc. Anthelmintic compounds
US10898484B2 (en) 2018-05-31 2021-01-26 Celltaxis, Llc Method of reducing pulmonary exacerbations in respiratory disease patients
CN109111376B (zh) * 2018-09-18 2021-09-14 四川医立特生物医药有限公司 一种2,5-双脱氧链霉胺衍生物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612332A (en) * 1984-03-19 1997-03-18 Alteon Inc. Di- and triaminoguanidines, and methods of use
JPS6428245A (en) 1987-07-22 1989-01-30 Sumitomo Electric Industries Production of fluoride glass
MX9202466A (es) 1991-05-24 1994-06-30 Vertex Pharma Compuestos inmunosupresores novedosos.
CO4520280A1 (es) * 1993-10-26 1997-10-15 Boehringer Ingelheim Pharma Derivados de pirrolidina, inhibidores de la bioscientesis de leucotrienos
DE19514313A1 (de) 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
US5859031A (en) 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5801197A (en) * 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5786378A (en) * 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
US5801187A (en) * 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5811434A (en) 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
US5780484A (en) 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5721256A (en) 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles

Also Published As

Publication number Publication date
HUP0103413A3 (en) 2002-10-28
HRP20010052A2 (en) 2001-12-31
CA2338214A1 (en) 2000-02-03
AU765925B2 (en) 2003-10-02
AU4285899A (en) 2000-02-14
DZ2851A1 (fr) 2004-02-04
EA003513B1 (ru) 2003-06-26
TNSN99147A1 (fr) 2005-11-10
MA24936A1 (fr) 2000-04-01
ES2191484T3 (es) 2003-09-01
PL345734A1 (en) 2002-01-02
EE200100044A (et) 2002-06-17
SV1999000102A (es) 2000-07-06
MY118222A (en) 2004-09-30
CN1611499A (zh) 2005-05-04
EP1100797B1 (en) 2003-02-26
HK1039779A1 (zh) 2002-05-10
EA200100052A1 (ru) 2001-06-25
IL140244A0 (en) 2002-02-10
EP1100797A1 (en) 2001-05-23
PA8478501A1 (es) 2000-05-24
NZ522270A (en) 2004-03-26
TR200100135T2 (tr) 2001-06-21
OA11585A (en) 2004-07-26
KR100468185B1 (ko) 2005-01-26
SI1100797T1 (en) 2003-06-30
GB9815880D0 (en) 1998-09-16
ID26991A (id) 2001-02-22
NO20010322L (no) 2001-03-15
CO5080782A1 (es) 2001-09-25
NZ508838A (en) 2002-12-20
BG105254A (en) 2001-10-31
KR100450008B1 (ko) 2004-09-24
KR20010071013A (ko) 2001-07-28
TWI229672B (en) 2005-03-21
DE69905582T2 (de) 2003-09-04
GEP20033028B (en) 2003-07-25
US6562964B1 (en) 2003-05-13
JP3795329B2 (ja) 2006-07-12
CA2338214C (en) 2006-08-01
CN1511837A (zh) 2004-07-14
CN1310718A (zh) 2001-08-29
GT199900115A (es) 2001-01-10
AR019427A1 (es) 2002-02-20
DE69905582D1 (de) 2003-04-03
WO2000005232A1 (en) 2000-02-03
US6372736B1 (en) 2002-04-16
PE20001037A1 (es) 2000-10-11
HUP0103413A2 (hu) 2002-05-29
KR20040062640A (ko) 2004-07-07
DK1100797T3 (da) 2003-04-22
BR9912330A (pt) 2001-04-17
JP2002521382A (ja) 2002-07-16
AP2001002046A0 (en) 2001-03-31
CR6073A (es) 2004-04-29
IS5790A (is) 2000-12-22
ATE233261T1 (de) 2003-03-15
JP2004002374A (ja) 2004-01-08
CN1174978C (zh) 2004-11-10
SK772001A3 (en) 2001-12-03
HN1999000106A (es) 1999-11-11

Similar Documents

Publication Publication Date Title
NO20010322L (no) Heterocykliske forbindelser som inhibitorer av rotamaseenzymer
DK1060178T3 (da) Heterocyklisk forbindelser som inhibitorer af rotamase enzymer
FI962800A0 (fi) Fenyyliheterosyklisiä yhdisteitä COX-2 inhibiittoreina
NO20001955L (no) Substituerte 4-amino-tiazol-2-yl forbindelser som inhibitorer av cyclinavhengige kinaser
IS5739A (is) Efnasambönd óstöðugra DP IV-lata
NO20014535L (no) Inhibitorer av IMPDH-enzym
NO20005673D0 (no) Heterocykliske inhibitorer av P38
NO20012984D0 (no) Succinoylamino benzodiazepiner som inhibitorer av AB proteinproduksjon
DK1001934T3 (da) Indolforbindelser som COX-2-inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
AU6895801A (en) Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
NO984917D0 (no) Ureaderivater som inhibitorer av IMPDH-enzym
NO20021042L (no) Benzofenoner som inhibitorer av reverstranskriptaser
DK1104420T3 (da) Substituerede 1,8-naphthyridin-4(1H)-oner som phosphodiesterase-4-inhibitorer
AU2002331311A1 (en) Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
NO20022649L (no) Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer
NO20022125D0 (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
NO20055565D0 (no) Anvendelse av derivater av 2,4-dihydro-[1,2,4]triazol-3-thion som inhibitorer av enzymet myeloperoksidase (MPO)
DK1228073T3 (da) Imidazolforbindelser som phosphodiesterase VII-inhibitorer
NO991316D0 (no) 3-mercaptoacetylamino-1,5-substituerte-2-okso-azepanderivater som er anvendbare som inhibitorer av matriksmetalloproteinase
NO20016403D0 (no) Substituerte purinderivater som inhibitorer av celleadhesjon
NO20001200D0 (no) Pyrrolopyrrolonderivater som inhibitorer av neurofil elastase
DK1222193T3 (da) Imidazolderivater som phosphodiesterase VII-inhibitorer
DK0944601T3 (da) Heterocykliske quanidinylaminoforbindelser som alfa-2-adrenoceptoragonister
ID18481A (id) 2-(3,5-difluorofenil)-3-(4-metilsulfonil)fenil)-2-siklopenten-1-on yang berguna sebagai inhibitor cox-2

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application